
Positive Phase 3 Results for New Antipsychotic in Psychosis
The results of the phase 3 EMERGENT-2 trial showed that KarXT, a combination of a muscarinic receptor agonist with an anticholinergic agent, led to significant improvements in symptoms of schizophrenia compared to a placebo. The treatment showed potential as a new class of effective and well-tolerated antipsychotic medication. It was associated with fewer side effects…